Mepivacaina Pierrel (Mepivacaine Hydrochloride)

Mepivacaine hydrochloride blocks voltage‑gated sodium channels on nerve membranes, preventing sodium influx that is essential for depolarisation. This inhibition stops the propagation of pain signals, resulting in a reversible loss of sensation in the tissues where the drug is administered.

The specific dose of Mepivacaina Pierrel is determined by the prescribing clinician based on the patient’s age, weight, the procedure being performed, and the maximum recommended dose for the product. Healthcare professionals calculate the appropriate volume to achieve effective anesthesia while staying within safety limits.

Safety data for mepivacaine hydrochloride in pregnancy and lactation are limited. Clinicians should evaluate the potential benefits against possible risks and consider alternative anesthetic options when treating pregnant or nursing patients. Consultation with obstetric specialists is recommended.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mepivacaina Pierrel belongs to the amide‑type local anesthetic class and offers a rapid onset similar to lidocaine but with a slightly longer duration of action and less vasodilatory effect. Compared with bupivacaine, it has a shorter half‑life, making it suitable for procedures that require moderate‑duration anesthesia without prolonged recovery.

The product should be stored below 25 °C in its original packaging, protected from light and moisture. Do not freeze the solution. Before use, inspect the vial for particulate matter or discoloration and allow it to reach room temperature if it has been refrigerated.

Mepivacaina Pierrel is administered by a qualified dental professional via infiltration or nerve block injection. The sterile solution is drawn into a syringe and injected into the targeted tissue area, following aseptic technique and appropriate dosage calculations.

Serious risks include allergic reactions such as rash or bronchospasm, cardiovascular toxicity like severe hypotension or arrhythmias, central nervous system toxicity leading to seizures, and prolonged numbness that may indicate systemic absorption. Immediate medical attention is required if any of these events occur.

Patients with a known hypersensitivity to amide‑type local anesthetics, those with severe cardiac conduction disorders, uncontrolled epilepsy, or who are taking certain Class I anti‑arrhythmic drugs should avoid Mepivacaina Pierrel. Clinicians must assess each individual’s medical history before administration.